⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29762475 | 1.00 | — | — | |
| SCHEMBL1274465 | 0.87 | MAPK14 (0.38) | — | |
| SCHEMBL29518274 | 0.72 | — | — | |
| SCHEMBL3297307 | 0.72 | — | — | |
| SCHEMBL22068158 | 0.72 | IDO1 (0.55) | — | |
| SCHEMBL31484874 | 0.72 | CCR1 (0.48) | — | |
| SCHEMBL1697620 | 0.72 | — | — | |
| SCHEMBL17669536 | 0.72 | CCR1 (0.48) | — | |
| SCHEMBL2643794 | 0.70 | — | — | |
| SCHEMBL26030813 | 0.70 | IDO1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 950 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112645927-A | Process for the preparation of a medicament | 基因泰克公司 | 2021-04-13 | — | — | CN | claimed |
| US-20200190061-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | claimed |
| US-20180134685-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2018-05-17 | — | — | US | claimed |
| US-20170022183-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2017-01-26 | — | — | US | claimed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4733303-A1 | MUSCARINIC M4 RECEPTOR AGONIST AND USE THEREOF | Haisco Pharmaceutical Group Co., Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| US-20260103483-A1 | Organometallic Complex And Light-Emitting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| WO-2003000689-A1 | IMIDAZO`1,2-A!PYRIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF HERPES VIRAL INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002078700-A1 | PYRALOPYRIDINES, PROCESS FOR THEIR PREPARATION AND USE AS THERAPTEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002078701-A1 | USE OF PYRAZOLOPYRIDINES AS THERAPEUTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002048148-A2 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002016359-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| CN-1318054-A | Novel compounds | ASTRA PHARMA PROD (SE) | 2001-10-17 | — | — | CN | disclosed |
| EP-1114029-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015614-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-23 | — | — | WO | disclosed |